Bio-Path Holdings Inc. (NASDAQ: BPTH)
$1.80
-0.1200 ( -6.25% ) 67.7K
Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. The company's drug candidate, prexigebersen, is in the efficacy portion of Phase 2 clinical trial for acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC) and combination with decitabine. The other drugs of the company are BP1002, BP1003, BP1001-A, and DNABILIZE.
Market Data
Open
$1.80
Previous close
$1.92
Volume
67.7K
Market cap
$4.04M
Day range
$1.89 - $2.01
52 week range
$1.59 - $30.00
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
8-k | 8K-related | 15 | Apr 18, 2024 |
8-k | 8K-related | 15 | Apr 15, 2024 |
8-k | 8K-related | 16 | Apr 04, 2024 |
8-k | 8K-related | 15 | Apr 02, 2024 |
8-k | 8K-related | 16 | Mar 27, 2024 |
8-k | 8K-related | 16 | Mar 26, 2024 |
8-k | 8K-related | 14 | Mar 13, 2024 |
8-k | 8K-related | 14 | Mar 11, 2024 |
8-k | 8K-related | 16 | Mar 08, 2024 |
10-k | Annual reports | 85 | Mar 07, 2024 |